Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis
- 1 October 2017
- journal article
- Published by Elsevier BV in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 13 (7), 2251-2262
- https://doi.org/10.1016/j.nano.2017.06.009
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Curcumin Inhibits Imiquimod-Induced Psoriasis-Like Inflammation by Inhibiting IL-1beta and IL-6 Production in MicePLOS ONE, 2013
- Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohortBritish Journal of Dermatology, 2013
- Nanocarrier based formulation of Thymoquinone improves oral delivery: Stability assessment, in vitro and in vivo studiesColloids and Surfaces B: Biointerfaces, 2013
- Comparative Effectiveness of Commonly Used Systemic Treatments or Phototherapy for Moderate to Severe Plaque Psoriasis in the Clinical Practice SettingArchives of Dermatology, 2012
- Delivery of phytochemical thymoquinone using molecular micelle modified poly(D, L lactide-co-glycolide) (PLGA) nanoparticlesNanotechnology, 2010
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisThe New England Journal of Medicine, 2010
- Role of interleukin-1β during pain and inflammationBrain Research Reviews, 2009
- Combination therapy to treat moderate to severe psoriasisJournal of the American Academy of Dermatology, 2004
- Treatment of psoriasis. Part 2. Systemic therapiesJournal of the American Academy of Dermatology, 2001
- IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses.JCI Insight, 1998